Results 141 to 150 of about 48,812 (228)

Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma

Clinical, Cosmetic and Investigational Dermatology, 2013
Giulio Tosti, Emilia Cocorocchio, Elisabetta PennacchioliDivisione Melanomi e Sarcomi, Istituto Europeo di Oncologia, Milano, ItalyAbstract: Approaches aimed at enhancement of the tumor specific response have provided proof for the rationale of ...
Tosti G, Cocorocchio E, Pennacchioli E
doaj  

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Environmental Asbestos Exposure as a Possible Pathway to Early‐Onset Pleural Mesothelioma: A Case From Afghanistan and Pakistan to London

Respirology Case Reports, Volume 14, Issue 10, October 2026.
We report a case of a 40‐year‐old male with malignant pleural mesothelioma with no prior occupational exposure to asbestos. Environmental exposure as a cause of MPM may come into focus through migration from high environmental asbestos exposure regions in patients with no known occupational exposure.
Sophie Mounouchos, Asmita Aggarwal, Asaad Ahmed Nafees, Emma Johnson, Paul Cullinan, Carl Reynolds   +5 more
wiley   +1 more source

Response evaluation of neoadjuvant therapy in MIBC: clinical trial‐derived evidence to guide practice

BJU International, Volume 138, Issue 4, Page 558-564, October 2026.
Objectives To review how response to neoadjuvant therapy (NAT) is assessed in clinical trials of muscle‐invasive bladder cancer (MIBC), and to determine whether trial‐derived evidence can inform response evaluation in contemporary practice. Subjects/Patients and Methods We searched PubMed, Embase and ClinicalTrials.gov through August 2025 for ...
Roberto Contieri, Bas W.G. van Rhijn, Richard Cathomas, Anja Lorch, Daniela Oprea‐Lager, Paramananthan Mariappan, Francesco Sanguedolce, Antoine G. van der Heijden, Laura S. Mertens, In collaboration with the EAU Imaging Section   +9 more
wiley   +1 more source

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1702-1712, October 2026.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot   +17 more
wiley   +1 more source

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis. [PDF]

Int J Clin Oncol
Nishio M, Hayashi H, Goto Y, Ikeda S, Yokoyama T, Tanaka H, Tambo Y, Hotta K, Fukuhara T, Daga H, Masubuchi K, Aoyama T, Tschaika M, Hu N, Mizutani H.   +14 more
europepmc   +1 more source

The evolving role of immunotherapy in ovarian cancer

Cancer, Volume 132, Issue 18, 15 September 2026.
Abstract Ovarian cancer remains a major cause of gynecologic cancer mortality; and, although immune checkpoint inhibitors have transformed treatment in other solid tumors, their activity in ovarian cancer has been limited by tumor heterogeneity, an immunosuppressive tumor microenvironment, and the lack of robust predictive biomarkers.
Ana Carolina Veneziani, Laura Venegas, Amit M. Oza   +2 more
wiley   +1 more source

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. [PDF]

Clin Cancer Res
Borghaei H, Balli D, Paz-Ares LG, Reck M, Lu S, Ramalingam SS, Brahmer JR, John T, Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Zurawski B, Pluzanski A, Lee JS, Agrawal S, Spires T, Neely J, Ip V, Eccles LJ, Chang H, Szustakowski JD, Bhatia S, Yadav A, Eddy N, Geese WJ, O'Byrne KJ.   +26 more
europepmc   +1 more source

Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy. [PDF]

J Immunother Cancer
Squifflet P, Saad ED, Kurt M, Larkin J, Mohr P, Moshyk A, Buyse M.   +6 more
europepmc   +1 more source

Cardiac Conduction Disorders in Melanoma Patients Treated with CTLA-4-Containing Versus PD-1-Only Immune Checkpoint Inhibitor Therapy: A Propensity Score-Matched Real-World Analysis. [PDF]

Cancers (Basel)
Awad A, Khodeir J, AlQudah Q, Saleh N, Chalhoub M, Alraies MC.   +5 more
europepmc   +1 more source